title: Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor.
abstract: OBJECTIVE
  HIV infection is associated with an atherogenic lipoprotein profile, and ritonavir-boosted protease inhibitors exacerbate this phenotype. We evaluated the effect of 45 days of rosuvastatin versus pravastatin on the low-density lipoprotein (LDL) size and the distribution of LDL subfractions in HIV-1 patients receiving boosted protease inhibitors with elevated LDL levels.
  
  
  METHODS
  Substudy of the randomized double-blind multicentre ANRS 126 VIHstatine trial.
  
  
  METHODS
  Twenty clinical centres in France.
  
  
  METHODS
  HIV-infected patients receiving boosted protease inhibitors with dyslipidaemia (LDL cholesterol > 4.1 mmol/l and triglycerides < 8.8 mmol/l).
  
  
  METHODS
  Rosuvastatin 10 mg/day (n = 39) or pravastatin 40 mg/day (n = 37) for 45 days.
  
  
  METHODS
  LDL size and distribution of LDL subfractions blindly assessed by gradient gel electrophoresis at baseline and at day 45.
  
  
  RESULTS
  Rosuvastatin was more effective than pravastatin in increasing the diameter of the LDL peak. The LDL diameter change was 0.33 ± 0.59 nm in the rosuvastatin group versus -0.01 ± 0.52 nm in the pravastatin group (P = 0.021). Rosuvastatin was also more effective in increasing significantly the percentage of large LDL (LDL1, P = 0.038; LDL2, P = 0.031) and in decreasing the percentage of small LDL (LDL3, P = 0.009).
  
  
  CONCLUSIONS
  Rosuvastatin was more effective than pravastatin in normalizing LDL size and LDL subfraction distributions, leading to a less atherogenic phenotype.
authors: Unité Fonctionnelle de Biochimie des Maladies Métaboliques, Service de Biochimie Métabolique, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Assistance Publique-Hôpitaux de Paris, France. randa.bittar@psl.aphp.fr
authors: Randa
authors: R
authors: Bittar
authors: Philippe
authors: P
authors: Giral
authors: Elisabeth
authors: E
authors: Aslangul
authors: Lambert
authors: L
authors: Assoumou
authors: Marc A
authors: MA
authors: Valantin
authors: Olga
authors: O
authors: Kalmykova
authors: Marie C
authors: MC
authors: Federspiel
authors: Corinne
authors: C
authors: Cherfils
authors: Dominique
authors: D
authors: Costagliola
authors: Dominique
authors: D
authors: Bonnefont-Rousselot
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D004311:Double-Blind Method; D050171:Dyslipidemias / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D005602:France; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D006679:HIV Seropositivity / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D015497:HIV-1 / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D017320:HIV Protease Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D017035:Pravastatin; D019438:Ritonavir